ONCSQ (OncoSec Medical) YoY EPS Growth: 52.17% (As of Jan. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OncoSec Medical YoY EPS Growth?

OncoSec Medical ONCSQ -90.00% YoY EPS Growth is 52.17% as of Jan. 2023.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. OncoSec Medical's YoY EPS Growth for the quarter that ended in Jan. 2023 was 52.17%.

OncoSec Medical's Earnings per Share (Diluted) for the three months ended in Jan. 2023 was $-2.65.

OncoSec Medical YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical YoY EPS Growth Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.02 56.00 40.33 46.48 36.50

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.94 36.00 27.59 18.33 52.17

OncoSec Medical YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

OncoSec Medical's YoY EPS Growth for the fiscal year that ended in Jul. 2022 is calculated as:

YoY EPS Growth (A: Jul. 2022 )
=(Earnings per Share (Diluted) (A: Jul. 2022 )-Earnings per Share (Diluted) (A: Jul. 2021 ))/ | Earnings per Share (Diluted) (A: Jul. 2021 ) |
=(-19.14--30.14)/ | -30.14 |
=36.50 %

OncoSec Medical's YoY EPS Growth for the quarter that ended in Jan. 2023 is calculated as:

YoY EPS Growth (Q: Jan. 2023 )
=(Earnings per Share (Diluted) (Q: Jan. 2023 )-Earnings per Share (Diluted) (Q: Jan. 2022 )) / | Earnings per Share (Diluted) (Q: Jan. 2022 )) |
=(-2.65--5.54)/ | -5.54 |
=52.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 52.17% mean?
OncoSec Medical (ONCSQ) has a YoY EPS Growth of 52.17% as of Jan. 2023. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for OncoSec Medical and its competitors.
Is OncoSec Medical's YoY EPS Growth too high?
OncoSec Medical's current YoY EPS Growth is 52.17%.
How does OncoSec Medical's YoY EPS Growth compare to NOVNQ and USRM?
OncoSec Medical's YoY EPS Growth of 52.17% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for OncoSec Medical and its competitors. OncoSec Medical's current YoY EPS Growth is 52.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current YoY EPS Growth of 52.17%. The current YoY EPS Growth is 52.17%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current YoY EPS Growth is 52.17% as of Jan. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.